Tags : Eosinophilic Esophagitis


Lucid Diagnostics Collaborates with the University of Pennsylvania to Evaluate

Shots: The Lucid-Penn agreement will evaluate Lucid’s EsoCheck esophageal cell collection device with Collect+Protect technology as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies to manage patients with EoE The study will assess 10 patients with suspected or established EoE scheduled for a clinically indicated upper endoscopy which will undergo esophageal sampling […]Read More

Biotech Regulatory

AstraZeneca Receives the US FDA’s Orphan Drug Designation for its

Shots: The US FDA has granted orphan drug designation to Fasenra (benralizumab) for the treatment of eosinophilic esophagitis (EoE) following OD designation for EGPA in Nov’2018 and for hypereosinophilic syndrome in Feb’2019              The FDA’s OD designation is granted to the new therapies intended for the treatment, diagnosis or prevention of rare diseases or disorders that […]Read More